Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

Johnson et al. (2010): Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain + (Adult male or female patients, who had bee … Adult male or female patients, who had been using strong opioids for at least one week to relieve pain associated with incurable malignancy; pain severity score of 4 or above on a 0-10 Numerical Rating Scale (NRS) on both days of the two-day baseline periodn both days of the two-day baseline period)
Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study + (Adult patients (≥18 years of age) with his … Adult patients (≥18 years of age) with histologic evidence of an incurable malignancy other than brain, breast, ovarian, or endometrial cancer; estimated life expectancy of ≥3 months; Eastern Cooperative Oncology Group performance status of 0 to 2, as judged by their primary oncologist; self-reported weight loss of at least 5 pounds (2.3 kg) during the preceding 2 months and/or a physician-estimated caloric intake of less than 20 calories/kg of body weight per day; believe, that loss of appetite or loss of weight was an ongoing probleme or loss of weight was an ongoing problem)
Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results + (Adult patients with a confirmed diagnosis … Adult patients with a confirmed diagnosis of solid or nonmyeloid malignancy scheduled to receive six courses of cumulative DDP-based regimens were enrolled if they had satisfactory liver and renal function, a life expectancy of at least 9 months, and a WHO performance score of 0–1.onths, and a WHO performance score of 0–1.)
Argyriou et al. (2006): Preventing Paclitaxel-Induced Peripheral neuropathy: A Phase 2 Trial of Vitamin E Supplementation + (Adult patients with a confirmed diagnosis … Adult patients with a confirmed diagnosis of solid or nonmyeloid malignancy scheduled to receive six courses of paclitaxel-based chemotherapy regimen were enrolled if they had satisfactory liver and renal function, a life expectancy of at least 9 months, and a WHO performance score of 0–1.onths, and a WHO performance score of 0–1.)
Portenoy et al. (2012): Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial + (Adult patients with active cancer and chronic pain (moderate or severe despite a stable opioid regimen that could not be made more effective by further opioid dose titration); stable, average pain: NRS: ≥4≤ 8 (no change in 3 days > 2 points))

Campos et al. (2011): Guarana (Paullinia cupana) Improves Fatigue in Breast Cancer Patients Undergoing Systemic Chemotherapy + (Adult woman (22-70 years) with Mamma-carcinoma)

Del Giglio (2013): Purified Dry Extract of Paullinia cupana (Guarana) (PC-18) for Chemotherapy-Related Fatigue in Patients with Solid Tumors: An Early Discontinuation Study + (Adults with a histological diagnosis of cancer at any stage who were receiving systemic chemotherapy.)
Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain + (Advanced cancer; ≥18 years of age; clinica … Advanced cancer; ≥18 years of age; clinical diagnosis of cancer-related pain that was unalleviated by an optimized maintenance dose of Step 3 opioid therapy (opioid therapy considered optimized if: 1) a dose increase was clinically inappropriate due to opioid-related side effects or 2) further efficacy benefit was not expected at higher doses (for the second definition, patients had to be receiving ≥90 mg morphine equivalents/day, inclusive of maintenance, and breakthrough opioids); each of three consecutive days during the screening period: ≥four opioid breakthrough analgesic episodes per day (averaged over the three days); a stable maintenance opioid therapy dose; average pain ≥four and ≤eight on a 0-10 Numerical Rating Scale (NRS); average pain scores on the NRS that did not change by more than two points (i.e., no more than a two-point difference between the highest and lowest scores, with all scores remaining between four and eight)l scores remaining between four and eight))
Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies + (Advanced incurable stage of cancer; ≥ 18 y … Advanced incurable stage of cancer; ≥ 18 years of age; clinical diagnosis of cancer-related pain unalleviated by an optimized maintenance dose of Step 3 opioid therapy; ≤ 4 opioid breakthrough analgesic episodes per day (averaged over the 3 days); stable maintenance opioid therapy dose; average pain ≥ 4 and ≤ 8 on a 0–10 NRS; average pain scores on the NRS that did not change by more than 2 points from the beginning to end of screening (i.e. no more than a 2-point difference between the highest and lowest scores, with all scores remaining between 4 and 8 with all scores remaining between 4 and 8)
Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies + (Advanced incurable stage of cancer; ≥18yea … Advanced incurable stage of cancer; ≥18years of age; clinical diagnosis of cancer-related pain unalleviated by an optimized maintenance dose of Step 3 opioid therapy; ≤4 opioid breakthrough analgesic episodes per day (averaged over the 3 days); stable maintenance opioid therapy dose; average pain ≥ 4 and ≤8 on a 0–10 NRS; average pain scores on the NRS that did not change by more than 2 points from the beginning to end of screening (i.e. no more than a 2-point difference between the highest and lowest scores, with all scores remaining between 4 and 8 with all scores remaining between 4 and 8)
Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…) + (Advanced, incurable cancer; cancer-related … Advanced, incurable cancer; cancer-related anorexia-cachexia syndrome; weight loss (≥ 5% over 6 months), not explained by other diseases or recent surgery; Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2: estimated life expectancy of 3 months; Creatinine, bilirubin, and transaminase values no higher than 3x the maximum normal value; Unchanged antineoplastic therapy for 4 weeks and unchanged supportive treatment (analgesics, sedatives, tranquilizers, and anticholinergics) for 1 week before baseline assessmentscs) for 1 week before baseline assessments)
Mansouri et al. (2016): The Effect of Aloe Vera Solution on Chemotherapy-Induced Stomatitis in Clients with Lymphoma and Leukemia: A Randomized Controlled Clinical Trial + (Age > 18 years; acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL); being under chemotherapy)
Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer + (Age > 18 years; squamous cell carcinoma … Age > 18 years; squamous cell carcinoma of the mouth, pharynx or larynx; performance status 0-1; ability to eat an adequate oral diet; no previous radiotherapy in the head and neck region; adequate bone marrow, liver and renal functions; no history of allergies to testing compounds no history of allergies to testing compounds)
Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial + (Age of at least 18 years; a diagnosis of lung cancer; patients receiving cisplatin-based regimens; patients receiving standard antiemetic therapy (5-HT3 RAs); the ability to swallow capsules; nonuse of self-prescribed therapies or complementary products)
Shooriabi et al. (2016): The effect of ginger extract on radiotherapy-oriented salivation in patients with xerostomia: A double-blind controlled study + (Age over 18 years, a dose of radiation rec … Age over 18 years, a dose of radiation received over 4,500 cGy, the radiation received during the period 6 to 7 weeks, minor and major salivary glands involvement, one or two sides of the face in the field of radiation, and over the last three months of receiving radiation. last three months of receiving radiation.)
Montazeri et al. (2013): Eﬀect of Herbal Therapy to Intensity Chemotherapy-Induced Nausea and Vomiting in Cancer Patients + (Age over 18, having the experience of chem … Age over 18, having the experience of chemotherapy with nausea and vomiting, having at least two chemotherapy episodes. Consists of 50-100 mg Cisplatin, with or without other chemotherapy agents with similar amount and prescription in two chemotherapy cycles without having any plans for radiotherapy among cycles, presence in ward for 24 hours ( in order to investigate the PRN), having no nausea and vomiting experiences for some reasons except for chemotherapy, lack of receiving PRN in 24 past hours, lack of treatment with corticosteroid drugs during considered cycles, lack of aﬄictions to hepatitis, digestion system block-age, brain malignancy and cerebral metastasis and clotting disorder on the basis of recorded information in ﬁles, lack of using the anti-clot drug in ﬁles, lack of using the anti-clot drug)
Raei et al. (2013): Effect of herbal therapy to intensity chemotherapy-induced nausea and vomiting in cancer patients + (Age over 18, having the experience of chem … Age over 18, having the experience of chemotherapy with nausea and vomiting, having at least two chemotherapy episodes. Consists of 50-100 mg Cisplatin, with or without other chemotherapy agents with similar amount and prescription in two chemotherapy cycles without having any plans for radiotherapy among cycles; presence in ward for 24 hours ( in order to investigate the PRN; having no nausea and vomiting experiences for some reasons except for chemotherapy; lack of receiving PRN in 24 past hours; lack of treatment with corticosteroid drugs during considered cycles; lack of afflictions to hepatitis, digestion system blockage, brain malignancy and cerebral metastasis and clotting disorder on the basis of recorded information in files; lack of using the anti-clot drugin files; lack of using the anti-clot drug)
Sahebnasagh et al. (2017): Successful Treatment of Acute Radiation Proctitis with Aloe Vera: A Preliminary Randomized Controlled Clinical Trial + (Age ≥18 years; cancer in the pelvic area, radiotherapy and acute proctitis (ARP))
Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy + (Aged 18–75 years, Grade ≥3 neuropathy, as … Aged 18–75 years, Grade ≥3 neuropathy, as determined by NCI-CTC criteria version 3.0, while receiving paclitaxel, cisplatin or vinblastine treatment, and/or grade ≥2 neuropathy persisting for at least one month after the discontinuation of either drug, and neurotoxicity for <6 months; at least one abnormality on electrophysiological examination; Karnofsky physical score (KPS) of ≥60; absolute neutrophil count of ≥1.5×109/l, hemoglobin count of ≥80 g/l, platelet count of ≥75×109/l, total bilirubin counts of 1.5-fold less than normal value, glutamic-pyruvic transaminase (GPT/ALT) and glutamic-oxalacetic transaminease (GOT/AST) no more than 2.5-fold greater than the normal value; normal blood urea nitrogen, serum creatinine and electrocardiogram (ECG) findings. During the study, the use of steroids, analgesic or neuroprotectant drugs was not permitted.se of steroids, analgesic or neuroprotectant drugs was not permitted.)
Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial + (Aged 75 years or younger with recent resected stage II cutaneous malignant melanoma; Hematopoietic, hepatic, and renal functionality within normal ranges)
Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study + (Aged >18 years, had a radiotherapy field covering more than one-third of the buccal mucosa)
Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study + (Aged >18 years, had a radiotherapy field covering more than one-third of the buccal mucosa)
Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study + (Aged >18 years, had a radiotherapy field covering more than one-third of the buccal mucosa)
Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis + (Aged >18 years, pathologically established stages III and IV advanced nasopharyngeal carcinoma (NPC), concomitant chemotherapy and radiotherapy (CCRT))
Fallahi et al. (2013): Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer? + (Aged less than 55 years, who were referred … Aged less than 55 years, who were referred to our institute for 131I therapy to ablate the remnant thyroid tissue or to treat metastatic tumor, were enrolled in this study; all patients were in a hypothyroid state with serum thyroid stimulating hormone levels higher than 25 mIU/llating hormone levels higher than 25 mIU/l)
Grimison et al. (2020): Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial + (Aged ≥18 years; any malignancy of any stag … Aged ≥18 years; any malignancy of any stage; receiving intravenouschemotherapy of moderate or high emetogenic risk; receive at least two more consecutive cycles; refractory CINV (defined as emesis, and/or nausea of moderate severity on a 5-point rating scale, and/or requiring use of rescue medications) in earlier chemotherapy cycles despite guideline-consistent antiemetic prophylaxis consisting of corticosteroids, a 5-HT3 antagonist,and an NK-1 antagonist with or without olanzapine where indicatedwith or without olanzapine where indicated)
Lian et al. (2014): Comparing the Effectiveness of Green Tea versus Topical Metronidazole Powder in Malodorous Control of Fungating Malignant Wounds in a Controlled Randomised Study + (All hospitalised patients with malodorous fungating malignant wounds were eligible to participate in the study)
Hajimohammadebrahim-Ketabforoush et al. (2019): Effect of Vitamin D Supplementation on Postcraniotomy Pain After Brain Tumor Surgery: A Randomized Clinical Trial + (At least 18 years of age with newly diagnosed brain tumor with serum level of 25 (OH) vitamin D ≤20 ng/dL)
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis + (At least 18 years of age, diagnosis of a hematologic cancer (leukemia or lymphoma), and non-smoker and non-alcoholic.)
Keshavarzi et al. (2019): The effect of vitamin D and E vaginal suppositories on tamoxifen-induced vaginal atrophy in women with breast cancer + (Being married, having stage 1 or 2 breast … Being married, having stage 1 or 2 breast cancer based on the surgery stage, age below 50, receiving tamoxifen, not undergoing chemotherapy or radiotherapy during the study, a normal Pap smear during the last 3 years, no proven malignancies in other parts of the body, being sexually active during the study, meeting at least one of the criteria set in the genitourinary atrophy self-assessment, vaginal pH ≥ 5 according to Chollet et al. study at the time of the study, and a Vaginal Maturation Index (VMI) ≤52 according to Speroff’s studydex (VMI) ≤52 according to Speroff’s study)
Özdelikara et al. (2017): The effect of reflexology on the quality of life with breast cancer patients + (Being older than 18, knowing the diagnosis of the disease, receiving no radiotherapy, receiving a epirubicin and cyclophosphamide, having received no reflexology therapy before, being literate in Turkish)